DK162057C - Fremgangsmaade til fremstilling af et immunogent kompleks - Google Patents

Fremgangsmaade til fremstilling af et immunogent kompleks

Info

Publication number
DK162057C
DK162057C DK478383A DK478383A DK162057C DK 162057 C DK162057 C DK 162057C DK 478383 A DK478383 A DK 478383A DK 478383 A DK478383 A DK 478383A DK 162057 C DK162057 C DK 162057C
Authority
DK
Denmark
Prior art keywords
immunogent
preparing
complex
procedure
immunogent complex
Prior art date
Application number
DK478383A
Other languages
English (en)
Other versions
DK478383D0 (da
DK478383A (da
DK162057B (da
Inventor
Bror Morein
Original Assignee
Bror Morein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bror Morein filed Critical Bror Morein
Publication of DK478383D0 publication Critical patent/DK478383D0/da
Publication of DK478383A publication Critical patent/DK478383A/da
Publication of DK162057B publication Critical patent/DK162057B/da
Application granted granted Critical
Publication of DK162057C publication Critical patent/DK162057C/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK478383A 1982-10-18 1983-10-17 Fremgangsmaade til fremstilling af et immunogent kompleks DK162057C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8205892 1982-10-18
SE8205892A SE8205892D0 (sv) 1982-10-18 1982-10-18 Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Publications (4)

Publication Number Publication Date
DK478383D0 DK478383D0 (da) 1983-10-17
DK478383A DK478383A (da) 1984-04-19
DK162057B DK162057B (da) 1991-09-09
DK162057C true DK162057C (da) 1992-02-10

Family

ID=20348235

Family Applications (1)

Application Number Title Priority Date Filing Date
DK478383A DK162057C (da) 1982-10-18 1983-10-17 Fremgangsmaade til fremstilling af et immunogent kompleks

Country Status (18)

Country Link
US (2) US4578269A (da)
EP (1) EP0109942B1 (da)
JP (1) JPH07112983B2 (da)
AR (1) AR243080A1 (da)
AT (1) ATE61228T1 (da)
AU (1) AU558258B2 (da)
CA (1) CA1243954A (da)
DE (2) DE109942T1 (da)
DK (1) DK162057C (da)
ES (1) ES526524A0 (da)
FI (1) FI80600C (da)
IE (1) IE57025B1 (da)
MX (1) MX7563E (da)
NO (1) NO163668C (da)
NZ (1) NZ205925A (da)
PT (1) PT77515B (da)
SE (1) SE8205892D0 (da)
ZA (1) ZA837603B (da)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804624A (en) * 1982-05-21 1989-02-14 The University Of Tennessee Research Corporation Passive agglutination assay for pseudorabies antibody
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US6090406A (en) * 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
SE8402861L (sv) * 1984-05-28 1985-11-29 Stefan Svenson Rening av biologiskt material
NL8403195A (nl) * 1984-10-19 1986-05-16 Nederlanden Staat Immunogene complexen en vaccins die deze bevatten.
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
EP0231039B1 (en) * 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation
ZA872203B (en) * 1986-04-28 1988-02-24 New York Blood Center Inc Complex immunogen containing synthetic peptides
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
US5374426A (en) * 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
US5976839A (en) * 1987-03-13 1999-11-02 Bioenterprises Pty Limited Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5583112A (en) * 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
DE3853079T3 (de) * 1987-12-04 2000-11-09 The Liposome Co.,Inc. Liposome hoher stabilität und verfahren zur herstellung und verwendung.
AU3048689A (en) * 1988-01-13 1989-08-11 University Of North Carolina At Chapel Hill, The Immunogenic peptides
US5039522A (en) * 1988-01-29 1991-08-13 New York Blood Center, Inc. Immunogens containing peptides with an attached hydrophobic tail for adsorption to hepatitis B virus surface antigen
DK199588D0 (da) * 1988-04-12 1988-04-12 Nordisk Droge & Kemikalie Vaccine
US5885589A (en) * 1988-04-12 1999-03-23 Intervet International B.V. Pasteurella vaccine
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
WO1989010938A1 (en) * 1988-05-04 1989-11-16 Dana-Farber Cancer Institute Protein micelles
GB8818415D0 (en) * 1988-08-03 1988-09-07 Animal Health Inst Vaccine
US6291228B1 (en) 1988-08-03 2001-09-18 Vericore Limited Vaccine
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0292996A (ja) * 1988-09-30 1990-04-03 Bror Morein アジュバントおよび脂質を含む複合体
US4981684A (en) * 1989-10-24 1991-01-01 Coopers Animal Health Limited Formation of adjuvant complexes
JP2852705B2 (ja) * 1989-09-15 1999-02-03 タノックス バイオシステムズ インコーポレイテッド 自己免疫疾患の治療
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
DE4220653A1 (de) * 1992-06-26 1994-01-13 Boehringer Mannheim Gmbh Verfahren und Mittel zum Nachweis eines Analyten enthaltend glykosidische Tenside
EP0604727A1 (en) * 1992-12-31 1994-07-06 American Cyanamid Company Improved immunogenicity of a vaccine by incorporation of a cytokine within an immune-stimulating complex containing an antigen
WO1995006729A1 (en) * 1993-09-03 1995-03-09 Mcgill University Differentially expressed leishmania genes and proteins
US5773011A (en) * 1993-09-27 1998-06-30 Gerbu Biotechnik Gmbh Method of preparing a synergistic immunological adjuvant formulation
GB9320597D0 (en) * 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6083513A (en) * 1993-11-16 2000-07-04 Gerbu Biotechnik Gmbh Method for increasing the yield of antibodies in the techniques of immunology
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU4369596A (en) * 1994-11-21 1996-06-17 Virginia L. Scofield Sperm as vaccine vectors
DE69636935T2 (de) * 1995-01-27 2007-11-22 Genencor International, Inc., Palo Alto Verfahren zur extraktion von enzymen unter verwendung von tensiden
DK0831897T3 (da) 1995-06-07 2001-04-30 Pfizer In ovo-vaccination mod coccidiosis
ES2158108T3 (es) * 1995-06-07 2001-09-01 Pfizer Vacunacion in ovo contra la coccidiosis.
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
GB9618119D0 (en) * 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
ZA9710606B (en) * 1996-12-05 1998-06-12 Akzo Nobel Nv Non-virulent Mycoplasma synoviae vaccine thereof.
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AUPO732997A0 (en) 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6455323B1 (en) 1997-07-03 2002-09-24 Pharmacia & Upjohn Company Anti-bacterial methods and materials
US6627205B2 (en) 1997-12-01 2003-09-30 Pfizer Incorporated Ovo vaccination against coccidiosis
US6495140B1 (en) 1998-01-12 2002-12-17 Her Majesty In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Canada Process for the isolation, recovery and purification of non-polar extractives
US6908770B1 (en) * 1998-07-16 2005-06-21 Board Of Regents, The University Of Texas System Fluid based analysis of multiple analytes by a sensor array
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
ATE464907T1 (de) * 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US6984378B1 (en) 1999-02-26 2006-01-10 Pfizer, Inc. Method for the purification, recovery, and sporulation of cysts and oocysts
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
BR0009663A (pt) 1999-04-09 2002-04-09 Upjohn Co Composições de vacinas antibacterianas
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AR025750A1 (es) * 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
MXPA02008748A (es) 2000-03-17 2003-02-24 Upjohn Co Materiales y metodos para vacuna antisalmonella.
US6764823B2 (en) 2000-04-06 2004-07-20 Pharmacia & Upjohn Company Antimicrobial methods and materials
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
DK2266603T3 (da) * 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
BR0114786A (pt) * 2000-10-18 2003-08-12 Glaxosmithkline Biolog Sa Composição imunogênica, método de tratamento de um paciente que sofre de, ou que é suscetìvel a, um câncer, e, uso de uma combinação de uma saponina, um oligotìdeo imunoestimulador e um antìgeno de câncer, e, método para a manufatura de uma composição
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
DE60229118D1 (de) 2001-04-04 2008-11-13 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
ES2351299T3 (es) 2001-08-30 2011-02-02 Embrex, Inc. Procedimientos mejorados para la producción de ooquistes.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
WO2004018683A1 (en) 2002-08-12 2004-03-04 Akzo Nobel N.V. Streptococcus uberis protein, nucleic acid sequence encoding the same and its use in a mastitis vaccine
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
US7125425B2 (en) * 2002-10-21 2006-10-24 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
AU2003296592A1 (en) 2002-11-20 2004-06-15 Crucell Holland B.V. Antigen-complexes
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
PT1648500E (pt) 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
JP4896021B2 (ja) 2004-05-21 2012-03-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 呼吸器系病原体ワクチンのためのアルファウイルスベクター
EP1755666B1 (en) 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Vaccine compositions comprising virosomes and a saponin adjuvant
KR100958505B1 (ko) * 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
US20090317420A1 (en) 2004-07-29 2009-12-24 Chiron Corporation Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
CA2587084C (en) 2004-10-08 2019-07-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Modulation of replicative fitness by using less frequently used synonym ous codons
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0606481A2 (pt) 2005-01-20 2009-06-30 Isconova Ab composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
ATE516817T1 (de) 2005-06-16 2011-08-15 Univ Gent Impfstoffe zur immunisierung gegen helicobacter
CN103550767B (zh) 2005-07-28 2017-04-19 硕腾服务有限责任公司 疫苗施用方法、新猫杯状病毒、及抗猫细小病毒和猫疱疹病毒的动物免疫方法
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
EP1945254A1 (en) 2005-10-07 2008-07-23 Pfizer Products Incorporated Vaccines and methods to treat canine influenza
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
KR20080089663A (ko) 2006-01-27 2008-10-07 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja) 2006-03-24 2009-09-24 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 冷蔵しないインフルエンザワクチンの保存
EP1998802A2 (en) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
SG173336A1 (en) 2006-03-31 2011-08-29 Novartis Ag Combined mucosal and parenteral immunization against hiv
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
CA2656474A1 (en) 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
ES2525732T3 (es) 2006-07-18 2014-12-29 Glaxosmithkline Biologicals S.A. Vacunas contra el paludismo
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
NZ577855A (en) 2006-12-27 2012-07-27 Pfizer Prod Inc Vaccination schedule to prevent canine disease
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2688284A1 (en) 2007-05-25 2008-12-04 Novartis Ag Streptococcus pneumoniae pilus antigens
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
HRP20120790T1 (hr) 2007-06-27 2013-01-31 Novartis Ag Cjepiva protiv influence sa niskom koliäśinom aditiva
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8287885B2 (en) 2007-09-12 2012-10-16 Novartis Ag GAS57 mutant antigens and GAS57 antibodies
EP2062594A1 (en) 2007-11-21 2009-05-27 Wyeth Farma, S.A. Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
EP3118213A1 (en) 2007-12-19 2017-01-18 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
AU2008339551B2 (en) 2007-12-21 2013-10-24 Glaxosmithkline Biologicals S.A. Mutant forms of streptolysin O
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
WO2010077717A1 (en) 2008-12-09 2010-07-08 Novavax, Inc. Modified rsv f proteins and methods of their use
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
CN102438650A (zh) 2009-03-06 2012-05-02 诺华有限公司 衣原体抗原
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
HUE031051T2 (en) 2009-06-05 2017-06-28 Infectious Disease Res Inst Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
EP2442826B1 (en) 2009-06-15 2015-07-08 National University of Singapore Influenza vaccine, composition, and methods of use
SG176807A1 (en) 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
CN102470168A (zh) * 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
US20110110980A1 (en) 2009-09-02 2011-05-12 Wyeth Llc Heterlogous prime-boost immunization regimen
CA2773637A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
GB0917002D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
WO2011048041A1 (en) 2009-10-19 2011-04-28 Intervet International B.V. Streptococcal combi-vaccine
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
US20130251719A1 (en) 2009-10-22 2013-09-26 Tiergesundheitsdienst Bayern E.V. Bone marrow aplasia with haemorrhagic disease in calves caused by novel pathogen
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
AU2011231574A1 (en) 2010-03-26 2012-10-11 Glaxosmithkline Biologicals S.A. HIV vaccine
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
WO2011130379A1 (en) 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EP2560985B1 (en) 2010-04-21 2016-06-29 Pharmaq AS Nucleic acid sequences of a fish virus and the use thereof
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
MY184736A (en) 2010-06-24 2021-04-20 Genentech Inc Compositions and methods containing alkylglycosides for stabilizing protein-containing formulations
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012010291A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
WO2012010290A1 (en) 2010-07-21 2012-01-26 Athera Biotechnologies Ab Diagnostic and therapeutic methods and compositions for metabolic disease
EP2595653B1 (en) 2010-07-23 2017-06-28 Novavax AB Influenza vaccine
US8628947B2 (en) 2010-08-30 2014-01-14 Intervet Inc. Potomac horse fever isolates
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130280322A1 (en) 2010-09-27 2013-10-24 Glaxosmithkline Biologicals S.A. Vaccine
GB201017519D0 (en) 2010-10-15 2010-12-01 Novartis Vaccines Inst For Global Health S R L Vaccines
US20130287808A1 (en) 2010-11-05 2013-10-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines for preventing meningococcal infections
WO2012066481A1 (en) 2010-11-15 2012-05-24 Pharmaq As New ethiological agent
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN103347536A (zh) 2010-12-08 2013-10-09 尼奥瓦克斯公司 强灭活且仍高免疫原性的疫苗及其制备方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012089749A1 (en) 2010-12-29 2012-07-05 Intervet International B.V. Salmonid alphavirus protein e2
WO2012089748A1 (en) 2010-12-29 2012-07-05 Intervet International B.V. Canine babesiosis vaccine antigen
JP6077858B2 (ja) 2011-01-07 2017-02-08 東亞合成株式会社 抗疎水性ペプチド抗体を得るための抗原調製方法
PL2667892T3 (pl) 2011-01-26 2019-09-30 Glaxosmithkline Biologicals Sa Schemat szczepień przeciwko rsv
EP2691111B1 (en) 2011-03-31 2017-09-20 Institut National de la Sante et de la Recherche Medicale (INSERM) Use of blood or tissue bacteriome for prediction, diagnosis and prevention of metabolic diseases and their cardiovascular complications
EP2508197A1 (en) 2011-04-07 2012-10-10 Neovacs Method for treating IFNalpha related conditions
AU2012238643B2 (en) 2011-04-07 2017-04-13 Neovacs Method for treating IFNalpha related conditions
UA114086C2 (xx) 2011-05-13 2017-04-25 Імуногенна композиція глікопротеїну g вірусу hendra і/або nipah
ES2651143T3 (es) 2011-05-13 2018-01-24 Glaxosmithkline Biologicals Sa Antígenos de F de prefusión del VRS
EP3508219A1 (en) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Self-replicating rna prime - protein boost vaccines
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
AR087811A1 (es) 2011-09-08 2014-04-16 Umc Utrecht Holding Bv Vacuna contra el staphylococcus aureus
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
TR201808733T4 (tr) 2011-10-03 2018-07-23 Mx Adjuvac Ab Kanser tedavisini ve gıda ile ilgili bileşikleri içeren tıp alanlarında amfipatik veya hidrofobik moleküller için taşıyıcı olarak nano-parçacıklar, preparasyon için proses ve bunların kullanımı.
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
LT2782598T (lt) 2011-11-23 2020-07-27 In3Bio Ltd. Rekombinantiniai baltymai ir jų terapinis panaudojimas
CN104185420B (zh) 2011-11-30 2017-06-09 埃默里大学 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
GB201200259D0 (en) 2012-01-09 2012-02-22 Ohlin Per M Novel therapies
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
WO2013119856A1 (en) 2012-02-07 2013-08-15 Infectious Disease Research Institute Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP2852414B9 (en) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningococcus serogroup x conjugate
WO2013180011A1 (ja) 2012-05-28 2013-12-05 東亞合成株式会社 抗菌ペプチド及びその利用
CN104853770A (zh) 2012-07-06 2015-08-19 诺华股份有限公司 免疫原性组合物及其应用
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014024026A1 (en) 2012-08-06 2014-02-13 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against rsv and b. pertussis
WO2014043189A1 (en) 2012-09-14 2014-03-20 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes viruses and use thereof in vaccines
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
CA2896552A1 (en) 2012-10-03 2014-04-10 Novartis Ag Immunogenic compositions
US9480727B2 (en) 2012-10-18 2016-11-01 Toagosei Co. Ltd. Synthetic peptide for inhibiting expression of type 2 TNF receptor and use thereof
SMT201800011T1 (it) 2012-11-30 2018-05-02 Glaxosmithkline Biologicals Sa Antigeni e combinazioni di antigeni di pseudomonas
CN105473604B (zh) 2013-03-13 2021-01-22 美国政府(由卫生和人类服务部的部长所代表) 融合前rsv f蛋白和其用途
JP6873530B2 (ja) 2013-03-15 2021-05-19 イン3バイオ・リミテッドIn3Bio Ltd. 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ）
US10058603B2 (en) 2013-03-15 2018-08-28 Glaxosmithkline Biologicals S.A. Vaccine
AU2014243149B2 (en) 2013-03-26 2017-11-23 The Pirbright Institute Stabilised FMDV capsids
WO2014163558A1 (en) 2013-04-01 2014-10-09 Moreinx Ab Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
AU2014333706A1 (en) 2013-10-11 2016-05-26 Fundacion Profesor Novoa Santos Live attenuated vaccines
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP3082856A1 (en) 2013-12-16 2016-10-26 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
IL246456B2 (en) 2013-12-31 2024-06-01 Access To Advanced Health Inst Formulations will be assembled into a single vial
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
WO2015164826A2 (en) 2014-04-24 2015-10-29 Rhode Island Hospital ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS
CA2951430A1 (en) 2014-06-13 2015-12-17 Glaxosmithkline Biologicals Sa Immunogenic combinations
US10759836B2 (en) 2014-07-18 2020-09-01 University Of Washington Cancer vaccine compositions and methods of use thereof
WO2016011324A2 (en) 2014-07-18 2016-01-21 Oregon Health & Science University 5'-triphosphate oligoribonucleotides
CN104250640A (zh) 2014-08-22 2014-12-31 普莱柯生物工程股份有限公司 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用
EP3188750B1 (en) 2014-09-03 2020-03-11 Intervet International B.V. Attenuated bovine coronavirus and related vaccines
WO2016050961A1 (en) 2014-10-03 2016-04-07 Intervet International B.V. Broad-spectrum vaccine against avian reovirus
EP3613764A1 (en) 2014-10-15 2020-02-26 Xenothera Composition with reduced immunogenicity
US10813993B2 (en) 2015-03-03 2020-10-27 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Display platform from bacterial spore coat proteins
CN111560355A (zh) 2015-03-20 2020-08-21 普莱柯生物工程股份有限公司 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用
US10954492B2 (en) 2015-06-10 2021-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Processes for production and purification of nucleic acid-containing compositions
MX2018002728A (es) 2015-09-03 2018-09-05 Novavax Inc Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas.
CN105770887A (zh) * 2016-03-04 2016-07-20 邓招红 一种用于hbv疫苗的佐剂及其制备方法
GB2551984B (en) 2016-06-30 2019-01-16 Pharmaq As Fish virus
CA3153265C (en) 2016-08-17 2026-01-20 Pharmaq As Sea lice vaccine
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
SG11201909265QA (en) 2017-04-19 2019-11-28 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
IL300235A (en) 2017-07-18 2023-03-01 In3Bio Ltd Synthetic proteins and their therapeutic uses
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
CA3078223A1 (en) 2017-09-08 2019-03-14 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
IL277274B2 (en) 2018-03-19 2024-02-01 Novavax Inc Multifunctional nanoparticle vaccines for influenza
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
CN112912097A (zh) 2018-08-23 2021-06-04 葛兰素史密丝克莱恩生物有限公司 免疫原性蛋白和组合物
AU2018449744A1 (en) 2018-11-16 2021-05-27 Versitech Limited Live attenuated influenza B virus compositions methods of making and using thereof
WO2020243115A1 (en) 2019-05-25 2020-12-03 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
CN114269792B (zh) 2019-06-25 2025-08-08 因斯瑞拜奥有限公司 稳定的嵌合合成蛋白及其治疗用途
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP3922255A1 (en) 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
CA3202549A1 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
WO2022136505A1 (en) 2020-12-23 2022-06-30 Xenothera Composition of pig polyclonal antibody for its use to treat and/or prevent antibody-dependent macrophage pro-inflammatory cytokine release in a passive anti-infectious immunotherapy
EP4124342A1 (en) 2021-07-28 2023-02-01 Prokarium Limited Cancer therapy with live attenuated bacteria
WO2023079528A1 (en) 2021-11-05 2023-05-11 King Abdullah University Of Science And Technology Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
US20250082745A1 (en) 2021-12-13 2025-03-13 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Bacteriophage lambda-vaccine system
GB2622559A (en) 2022-05-10 2024-03-27 Johan Frostegaard Compositions, methods and uses
CN119522106A (zh) 2022-05-16 2025-02-25 硕腾服务有限责任公司 针对粘性摩替亚氏菌的疫苗
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
GB202215134D0 (en) 2022-10-13 2022-11-30 Prokarium Ltd Composition
GB202215576D0 (en) 2022-10-21 2022-12-07 Prokarium Ltd Circuit
WO2024130009A1 (en) 2022-12-14 2024-06-20 Yale University Compositions and methods of use thereof for the treatment of virally driven cancers
US20250085282A1 (en) 2023-09-11 2025-03-13 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025068401A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 15 variant
US20250144200A1 (en) 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
WO2025109155A1 (en) 2023-11-24 2025-05-30 Prokarium Limited Interleukin variant
WO2025224251A1 (en) 2024-04-24 2025-10-30 Prokarium Limited Modified microorganisms
GB202405780D0 (en) 2024-04-24 2024-06-05 Prokarium Ltd Vacuole escape
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
WO2025264964A1 (en) 2024-06-20 2025-12-26 Zoetis Services Llc Vaccines against tenacibaculum finnmarkense
WO2026022584A1 (en) 2024-07-22 2026-01-29 Glaxosmithkline Biologicals Sa Methods of delaying dementia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1083815A (en) * 1963-10-01 1967-09-20 Wellcome Found Vaccine adjuvants
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4196191A (en) * 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
US4148876A (en) * 1975-09-29 1979-04-10 Burroughs Wellcome Co. Biological preparations
US4201767A (en) * 1978-11-08 1980-05-06 Merck & Co., Inc. Viral liposome particle
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
DE3173713D1 (en) * 1980-09-05 1986-03-20 Frappier Armand Inst Formation of an immunosome exclusively made of viral antigens reconstituted on an artificial membrane
CA1206094A (en) * 1981-01-09 1986-06-17 Thomas P. Hopp Synthetic antigenic composition and process for making same
GB2093039B (en) * 1981-01-29 1984-06-06 Nat Res Dev Improvements relating to hepatitis b vaccine
EP0058021A3 (en) * 1981-02-06 1982-10-27 Beecham Group Plc Pharmaceutical compositions
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin

Also Published As

Publication number Publication date
IE57025B1 (en) 1992-03-25
PT77515A (en) 1983-11-01
EP0109942A2 (en) 1984-05-30
DE3382190D1 (de) 1991-04-11
PT77515B (en) 1986-04-16
DK478383D0 (da) 1983-10-17
US4744983A (en) 1988-05-17
DE109942T1 (de) 1984-12-06
ES8503951A1 (es) 1985-04-01
AU2010383A (en) 1984-05-03
IE832394L (en) 1984-04-18
AU558258B2 (en) 1987-01-22
FI80600C (fi) 1990-07-10
FI833748A0 (fi) 1983-10-14
FI80600B (fi) 1990-03-30
DK478383A (da) 1984-04-19
EP0109942A3 (en) 1985-08-14
DK162057B (da) 1991-09-09
CA1243954A (en) 1988-11-01
AR243080A1 (es) 1993-07-30
JPH07112983B2 (ja) 1995-12-06
NZ205925A (en) 1987-10-30
ES526524A0 (es) 1985-04-01
EP0109942B1 (en) 1991-03-06
FI833748A7 (fi) 1984-04-19
ZA837603B (en) 1984-12-24
NO163668B (no) 1990-03-26
JPS59186921A (ja) 1984-10-23
MX7563E (es) 1989-10-17
ATE61228T1 (de) 1991-03-15
NO163668C (no) 1990-07-04
SE8205892D0 (sv) 1982-10-18
US4578269A (en) 1986-03-25
NO833769L (no) 1984-04-24

Similar Documents

Publication Publication Date Title
DK162057C (da) Fremgangsmaade til fremstilling af et immunogent kompleks
DK350083D0 (da) Fremgangsmade til fremstilling af phenylethanolaminer
DK470583A (da) Fremgangsmaade til fremstilling af 1-phenyl-2-piperidinopropanolderivater
DK156283D0 (da) Fremgangsmade til fremstilling af fedt-glykosid-blandinger
DK183583D0 (da) Fremgangsmade til fremstilling af benzoazacycloalkyl-spiro-imidazolidiner
DK299483A (da) Fremgangsmaade til fremstilling af n-phosphonomethylglycin
DK153583A (da) Fremgangsmaade til fremstilling af substituerede penemderivater
DK211783A (da) Fremgangsmaade til fremstilling af pyrazolpyridinforbindelser
DK283083D0 (da) Fremgangsmade til fremstilling af n-phosphonomethylglycin
DK451883D0 (da) Fremgangsmade til fremstilling af 4-methyl-5-alkylthiometyl-imidazoler
DK71783D0 (da) Fremgangsmade til fremstilling af pyrimidonderivater
DK40883D0 (da) Fremgangsmade til fremstilling af benzothienylallylaminer
DK394783A (da) Fremgangsmaade til fremstilling af n-phosphonomethylglycin
DK361983A (da) Fremgangsmaade til fremstilling af meldroejealkaloider
DK399783D0 (da) Fremgangsmade til fremstilling af substituerede 1-puridyloxy-3-indolylalkylamino-2-propanoler
DK385983D0 (da) Fremgangsmade til fremstilling af 1-oxacephamer
DK411881A (da) Fremgangsmaade til fremstilling af 1-oxa-beta-lactamantibiotika
DK380981A (da) Fremgangsmaade til fremstilling af benzoquinoliziner
DK362381A (da) Fremgangsmaade til fremstilling af polyazaheterocycliske fordelser
DK9383D0 (da) Fremgangsmade til fremstilling af phosphinoxider
DK193983D0 (da) Fremgangsmade til fremstilling af substituerede phenylendiaminer
DK432683D0 (da) Fremgangsmade til fremstilling af 2-hydroxy-2-phenylethylaminer
DK108283D0 (da) Fremgangsmade til fremstilling af pentacycliske forbindelser
DK1181A (da) Fremgangsmaade til fremstilling af halogenalkener
DK534281A (da) Fremgangsmaade til fremstilling af 1-sulfo-2-oxozetidinderivater

Legal Events

Date Code Title Description
PUP Patent expired